Heart attacks are one of the leading causes of death around the world. They occur when blood flow to part of the heart is suddenly blocked, usually by a clot in a coronary artery. When this happens, the heart muscle is deprived of oxygen.
Without oxygen, heart cells begin to die within minutes. Doctors work quickly to reopen the blocked artery using treatments such as emergency angioplasty or clot‑busting medicines. However, even after the main artery is reopened, many patients still experience additional damage inside the heart.
A common problem after a heart attack is something doctors call the “no‑reflow” phenomenon. This occurs when the tiny blood vessels inside the heart muscle remain narrowed or blocked even after the main artery has been cleared.
As a result, blood cannot fully reach parts of the heart tissue. Studies suggest that this complication occurs in up to half of heart attack patients. When it happens, the risk of future problems such as heart failure, repeated hospital visits, or even death becomes much higher.
A new study led by researchers from the University of Bristol and University College London (UCL) suggests that a group of medications already used for weight loss and diabetes may help solve this problem.
These drugs mimic a natural hormone in the body called GLP‑1, which stands for glucagon‑like peptide‑1. GLP‑1 drugs have become very popular in recent years because they can help people lose weight and improve blood sugar control in type 2 diabetes.
The researchers found that these medications may also help protect the heart after a heart attack by improving blood flow in the smallest blood vessels. Their findings were published in the scientific journal Nature Communications.
Previous research had already shown that GLP‑1 medications can lower the risk of serious heart problems in people with diabetes or obesity. Interestingly, these benefits seem to appear even when patients do not lose a large amount of weight. This led scientists to wonder whether the drugs might have direct protective effects on the heart itself.
To investigate this question, the research team looked closely at what happens inside the heart during a heart attack. Earlier studies had shown that small contractile cells called pericytes play an important role.
These cells wrap around tiny blood vessels known as capillaries. During a heart attack, the lack of oxygen can cause pericytes to tighten. When they contract, they squeeze the capillaries and restrict blood flow even after the main artery has been reopened.
In the new study, the scientists examined whether GLP‑1 drugs could relax these cells and help restore blood flow.
Dr. Svetlana Mastitskaya, a senior lecturer in cardiovascular regenerative medicine at Bristol Medical School and the lead author of the study, explained that this narrowing of small blood vessels is a major reason why many patients experience the no‑reflow complication.
According to Dr. Mastitskaya, even when emergency treatment successfully clears the main blocked artery, the tiny blood vessels inside the heart muscle may remain constricted. When this happens, oxygen‑rich blood cannot reach all areas of the heart. This lack of circulation can cause additional damage to heart tissue.
To test their theory, the researchers conducted experiments using animal models of heart attacks. They discovered that GLP‑1 drugs were able to improve blood flow in the heart after an attack.
The medications activated special structures in cells known as potassium channels. When these channels were activated, the pericytes relaxed. As the cells relaxed, the tiny blood vessels widened and allowed blood to pass through more easily.
This improved circulation helped restore oxygen supply to heart tissue that might otherwise have remained damaged. In simple terms, the drugs appeared to help reopen the smallest blood vessels inside the heart, reducing the chance of long‑term injury.
Professor David Attwell, the Jodrell Professor of Physiology at UCL and co‑leader of the study, said the findings are particularly exciting because many GLP‑1 drugs are already widely used in clinical practice. These medications are currently prescribed for conditions such as type 2 diabetes, obesity, and even some kidney diseases.
Because the drugs are already approved and well studied, scientists believe they might potentially be repurposed to help heart attack patients. If further research confirms these results in human trials, doctors might one day use GLP‑1 medications to reduce the risk of the no‑reflow complication after heart attacks.
The study also highlights how modern medicine is increasingly discovering new uses for existing drugs. Instead of developing entirely new medications from scratch, researchers sometimes find that treatments designed for one condition may help with others as well.
When reviewing the findings of this research, several important points stand out. First, the study provides a clearer explanation for how GLP‑1 drugs may protect the heart beyond their effects on weight loss and blood sugar. By targeting the tiny blood vessels inside the heart, these medications may help prevent additional damage after a heart attack.
Second, the research identifies pericytes and potassium channels as important targets for future treatments. Understanding how these small cells control blood flow may open new directions for developing therapies aimed at improving heart recovery.
However, it is also important to recognize the limitations of the study. Much of the research was conducted using animal models rather than large clinical trials in humans. While the results are promising, further studies involving heart attack patients will be needed to confirm whether the same benefits occur in real medical settings.
Even so, the findings represent an encouraging step forward in cardiovascular research. If future studies confirm the results, GLP‑1 drugs could become part of a new strategy to improve recovery after heart attacks and reduce long‑term complications.
Overall, the research suggests that medications originally developed for diabetes and weight loss may also play a role in protecting the heart. By improving blood flow in the smallest vessels of the heart muscle, these drugs may help doctors prevent further damage and improve survival after a heart attack.
If you care about heart disease, please read studies about a big cause of heart failure, and common blood test could advance heart failure treatment.
For more health information, please see recent studies about a new way to repair human heart, and results showing drinking coffee may help reduce heart failure risk.
Copyright © 2026 Knowridge Science Report. All rights reserved.
